1.250
-0.020
(-1.57%)
At close: 3:58:39 PM GMT+8
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
1,467,798
1,467,798
1,267,598
1,595,543
1,445,915
Cost of Revenue
847,323
847,323
728,680
975,021
884,832
Gross Profit
620,475
620,475
538,918
620,522
561,083
Operating Expense
332,287
332,287
268,829
400,133
326,520
Operating Income
288,188
288,188
270,089
220,389
234,563
Net Non Operating Interest Income Expense
-54,702
-54,702
-43,537
-23,798
-28,056
Pretax Income
254,583
254,583
250,345
231,433
220,569
Tax Provision
44,414
44,414
42,976
43,728
34,264
Net Income Common Stockholders
266,968
266,968
251,044
177,666
173,713
Diluted NI Available to Com Stockholders
266,968
266,968
251,044
177,666
173,713
Basic EPS
0.14
--
0.13
0.09
0.09
Diluted EPS
0.14
--
0.13
0.09
0.09
Basic Average Shares
1,911,361
--
1,920,196
1,915,677
1,916,167
Diluted Average Shares
1,911,361
--
1,920,196
1,915,677
1,916,167
Total Operating Income as Reported
333,126
333,126
313,384
260,888
256,240
Rent Expense Supplemental
--
6,708
499
812
--
Total Expenses
1,179,610
1,179,610
997,509
1,375,154
1,211,352
Net Income from Continuing & Discontinued Operation
266,968
266,968
251,044
177,666
173,713
Normalized Income
185,062.899
185,062.899
177,867.090
174,581.556
165,393.514
Interest Income
24,006
24,006
17,875
1,889
2,088
Interest Expense
78,708
78,708
61,412
25,687
30,144
Net Interest Income
-54,702
-54,702
-43,537
-23,798
-28,056
EBIT
333,291
333,291
311,757
257,120
250,713
EBITDA
333,291
489,813
496,217
449,717
442,414
Reconciled Cost of Revenue
847,323
847,323
728,680
975,021
884,832
Reconciled Depreciation
--
156,522
184,460
192,597
191,701
Net Income from Continuing Operation Net Minority Interest
186,359
186,359
175,204
177,666
173,710
Total Unusual Items Excluding Goodwill
1,570
1,570
-3,215
3,803
9,846
Total Unusual Items
1,570
1,570
-3,215
3,803
9,846
Normalized EBITDA
331,721
488,243
499,432
445,914
432,568
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
273.899
273.899
-551.910
718.556
1,529.514
3/31/2021 - 9/21/2016
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
2161.HK JBM (Healthcare) Limited
2.000
-3.38%
BFK.SI Pharmesis International Ltd.
0.6050
0.00%
TKUN.TA Tikun Olam-Cannbit Pharmaceuticals Ltd
38.90
0.00%
3737.HK Zhongzhi Pharmaceutical Holdings Limited
0.900
0.00%
0460.HK SIHUAN PHARM
0.640
+1.59%
1011.HK NT PHARMA
0.280
+18.64%
1061.HK ESSEX BIO-TECH
4.450
-3.05%
3933.HK The United Laboratories International Holdings Limited
13.380
+0.45%
3692.HK Hansoh Pharmaceutical Group Company Limited
22.150
-2.85%
0013.HK HUTCHMED
22.550
-1.96%